Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Harvard Bioscience (HBIO) Net Margin (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Net Margin for 15 consecutive years, with 5.98% as the latest value for Q3 2025.

  • On a quarterly basis, Net Margin rose 1583.0% to 5.98% in Q3 2025 year-over-year; TTM through Sep 2025 was 76.73%, a 6240.0% decrease, with the full-year FY2024 number at 12.85%, down 1001.0% from a year prior.
  • Net Margin was 5.98% for Q3 2025 at Harvard Bioscience, up from 11.38% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 8.34% in Q2 2022 to a low of 230.98% in Q1 2025.
  • A 5-year average of 21.12% and a median of 5.8% in 2023 define the central range for Net Margin.
  • Peak YoY movement for Net Margin: skyrocketed 2690bps in 2023, then plummeted -21183bps in 2025.
  • Harvard Bioscience's Net Margin stood at 1.78% in 2021, then plummeted by -421bps to 5.73% in 2022, then decreased by -1bps to 5.8% in 2023, then crashed by -825bps to 53.69% in 2024, then skyrocketed by 89bps to 5.98% in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Net Margin are 5.98% (Q3 2025), 11.38% (Q2 2025), and 230.98% (Q1 2025).